George Orphanides

George Orphanides is the Chief Scientific Officer at invoX Pharma, where George oversees the R&D strategy for immunotherapy of cancer and mRNA vaccines. George is also a Non-Executive Director at pHion Therapeutics Limited and the Founder and Project Leader of the Alderley Park Oncology Development Programme. With a background in oncology alliances and therapeutic technologies evaluation at AstraZeneca, George has extensive experience in strategic collaborations and drug development. With a PhD in Biochemistry and post-doctoral fellowship in Gene regulation and Epigenetics, George brings a wealth of scientific expertise to their roles in the pharmaceutical and biotechnology industry.